Extended depth of focus lens implantation after radial keratotomy.

To identify the visual performance of radial keratotomy (RK) patients that have undergone cataract surgery with implantation of an extended depth of focus (EDOF) intraocular lens (IOL). Retrospective chart review with questionnaire. Medical charts of patients with a history of RK that had undergone phacoemulsification with implantation of the Tecnis Symfony IOL (J&J Vision) were reviewed. Data collected included preoperative demographics, number of RK incisions, pupil size, and preoperative visual acuity and manifest refraction. Primary outcome measures of the study included postoperative uncorrected distance visual acuity (UCVA) and manifest refraction spherical equivalent (SE) at each follow-up visit. Secondary outcomes included results from a telephone questionnaire assessing visual performance and satisfaction. Twenty-four eyes of 12 patients were included. UCVA improved from an average Snellen equivalent 20/73 preoperatively to 20/33 at an average final follow-up of 6 months ( An EDOF lens implant can produce good visual outcomes and satisfaction in patients with a history of RK.

Déclaration de conflit d'intérêts

Drs Berdahl and Thompson have received consultant fees from Johnson and Johnson Vision. Dr Berdahl reports personal fees from Alcon, Allergan, Avedro, Aurea Medical, Bausch and Lomb, CorneaGen, Dakota Lions Eye Bank, Equinox, Expert Opinion, Glaukos, Gore, Imprimis/Harrow Health, Johnson and Johnson, Kala, Kedalion, MELT Pharmaceuticals, MicroOptx, New World Medical, Ocular Surgical Data, Ocular Theraputix, Omega Ophthalmic, Orasis, Oyster Point, RxSight, Surface INC, Tarsus, Tear Clear, Vittamed, Vance Thompson Vision, Verana Health, Visionary Ventures, Zeiss, during the conduct of the study. Dr Thompson reports personal fees from Alcon, Bausch & Lomb, Johnson & Johnson, Zeiss, during the conduct of the study and personal fees from Acufocus, Allergan, Allotex, Avellino, BRIM Biotechnology, Inc, Conjtac, CSO (Costruzione Strumenti Oftalmici), Equinox, Euclid Systems, eyeBrain Medical Inc, Eyedetec, EyeGate Pharma, Healthe, Imprimis, Mynosys, Novaliq, OPHTEC, ORA (Ora Inc), Oyster Point Pharma, Precision Lens, RxSight, SightSciences, Stuart Therapeutics, Tarsus Rx, TearClear, ThruFocus, Treehouse Health, Veracity, Visant, Visiometrics, Vivior AG, outside the submitted work. The authors report no other conflicts of interest in this work.